abciximab glycoprotein iibiiia receptor antagonist manufactured janssen biologics bv distributed eli lilly trade name reopro platelet aggregation inhibitor mainly used coronary artery procedures like angioplasty prevent platelets sticking together causing thrombus blood clot formation within coronary artery glycoprotein iibiiia abciximab short plasma halflife due strong affinity receptor platelets may occupy receptors weeks practice platelet aggregation gradually returns normal hours discontinuation drug abciximab made fab fragments immunoglobulin targets glycoprotein iibiiia receptor platelet abciximab indicated use individuals undergoing percutaneous coronary intervention angioplasty without stent placement use abciximab setting associated decreased incidence ischemic complications due decreased need repeated coronary artery revascularization first month following research also shows drug use patients diabetes chronic kidney disease appropriate drug choice patient scheduled emergency surgery ie heart surgery bleeding time may take hours normalize pediatric uses include treatment kawasaki disease abciximab plasma halflife ten minutes second phase halflife minutes however effects platelet function seen hours infusion terminated low levels glycoprotein iibiiia receptor blockade present days infusion terminated abciximab require dose adjustments patients kidney many side effects abciximab due antiplatelet effects increase risk bleeding common type bleeding due abciximab gastrointestinal hemorrhage thrombocytopenia rare known serious risk characterized severe drop platelets circulating blood abciximab induced thrombocytopenia usually rapid occurring hours administration may occur days transfusing platelets known treatment abciximabinduced thrombocytopenia therapy may limited effectiveness drug may bind inhibit receptors newly transfused platelets httpsenwikipediaorgwikiabciximab